Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder

Craig A. Erickson, Logan K. Wink, Maureen C. Early, Elizabeth Stiegelmeyer, Lauren Mathieu-Frasier, Vanessa Patrick, Christopher J. McDougle

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. Materials and methods: We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5-17 years with autistic disorder. Results: Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of "very much improved" or "much improved" on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Conclusion: Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit.

Original languageEnglish
Pages (from-to)981-987
Number of pages7
JournalJournal of Autism and Developmental Disorders
Volume44
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Autistic Disorder
Placebos
Checklist
Synaptic Transmission
Pharmaceutical Preparations
gamma-Aminobutyric Acid
Glutamic Acid
Therapeutics
Autism Spectrum Disorder
acamprosate

Keywords

  • Acamprosate
  • Autism spectrum disorder
  • Gamma-aminobutyric acid
  • Glutamate

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Cite this

Erickson, C. A., Wink, L. K., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., Patrick, V., & McDougle, C. J. (2014). Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. Journal of Autism and Developmental Disorders, 44(4), 981-987. https://doi.org/10.1007/s10803-013-1943-3

Brief report : Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. / Erickson, Craig A.; Wink, Logan K.; Early, Maureen C.; Stiegelmeyer, Elizabeth; Mathieu-Frasier, Lauren; Patrick, Vanessa; McDougle, Christopher J.

In: Journal of Autism and Developmental Disorders, Vol. 44, No. 4, 2014, p. 981-987.

Research output: Contribution to journalArticle

Erickson, CA, Wink, LK, Early, MC, Stiegelmeyer, E, Mathieu-Frasier, L, Patrick, V & McDougle, CJ 2014, 'Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder', Journal of Autism and Developmental Disorders, vol. 44, no. 4, pp. 981-987. https://doi.org/10.1007/s10803-013-1943-3
Erickson, Craig A. ; Wink, Logan K. ; Early, Maureen C. ; Stiegelmeyer, Elizabeth ; Mathieu-Frasier, Lauren ; Patrick, Vanessa ; McDougle, Christopher J. / Brief report : Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. In: Journal of Autism and Developmental Disorders. 2014 ; Vol. 44, No. 4. pp. 981-987.
@article{9b4be7bfc01b4a2e8435bb15eb9c504e,
title = "Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder",
abstract = "Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. Materials and methods: We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5-17 years with autistic disorder. Results: Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of {"}very much improved{"} or {"}much improved{"} on the Clinical Global Impressions Improvement scale) and ≥25 {\%} improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Conclusion: Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit.",
keywords = "Acamprosate, Autism spectrum disorder, Gamma-aminobutyric acid, Glutamate",
author = "Erickson, {Craig A.} and Wink, {Logan K.} and Early, {Maureen C.} and Elizabeth Stiegelmeyer and Lauren Mathieu-Frasier and Vanessa Patrick and McDougle, {Christopher J.}",
year = "2014",
doi = "10.1007/s10803-013-1943-3",
language = "English",
volume = "44",
pages = "981--987",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Brief report

T2 - Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder

AU - Erickson, Craig A.

AU - Wink, Logan K.

AU - Early, Maureen C.

AU - Stiegelmeyer, Elizabeth

AU - Mathieu-Frasier, Lauren

AU - Patrick, Vanessa

AU - McDougle, Christopher J.

PY - 2014

Y1 - 2014

N2 - Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. Materials and methods: We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5-17 years with autistic disorder. Results: Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of "very much improved" or "much improved" on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Conclusion: Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit.

AB - Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. Materials and methods: We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5-17 years with autistic disorder. Results: Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of "very much improved" or "much improved" on the Clinical Global Impressions Improvement scale) and ≥25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Conclusion: Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit.

KW - Acamprosate

KW - Autism spectrum disorder

KW - Gamma-aminobutyric acid

KW - Glutamate

UR - http://www.scopus.com/inward/record.url?scp=84896373801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896373801&partnerID=8YFLogxK

U2 - 10.1007/s10803-013-1943-3

DO - 10.1007/s10803-013-1943-3

M3 - Article

C2 - 24052275

AN - SCOPUS:84896373801

VL - 44

SP - 981

EP - 987

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 4

ER -